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Abstract: The canine eye is an immune-privileged organ that is provided with systems to prevent and control 
the local immune response, which could have a detrimental impact. The entry of blood-derived antigens is hin-
dered by the blood-ocular barriers and potential invading pathogens are tackled by local antimicrobial molecules. 
Despite the existence of numerous immune-competent cells, the anterior chamber of the eye is characterised by 
low responsiveness. This review is focused on the innate and adaptive immunity employed to control health and 
disease in the canine eye.
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1. Introduction
The eye’s surface is outward-facing, and it is thus 
threatened by a number of antigenic molecules and 
pathogens. As a mucosa, it is defended by mucosal 
immunity, which includes innate and adaptive 
systems locally found in tear film and tissue. The 
immune response carries out two conflicting func-
tions: the degradation of invasive microorganisms 
is outweighed by the control of inflammatory reac-
Contents
1. Introduction
2. Ocular innate immunity
3. Ocular adaptive immunity
3.1 APCs, lymphocytes and plasma cells
3.1.1 The ocular APCs
3.1.2 Cell-mediated immunity: immune toler-
ance or inflammatory response?
3.1.3 Humoral immunity: secretory IgA and 
other immunoglobulins
3.2 The retina and its immunity
3.2.1 The glia cells
3.2.2 The retinal pigment epithelium
4. Ocular immunity in the elderly
5. Ocular immune privilege
6. Ocular immunity in disease
7. With an eye to the future: corneal grafting in the 
dog
8. Concluding remarks and perspectives
9. References
2Review Article Veterinarni Medicina, 64, 2019 (01): 1–17
https://doi.org/10.17221/137/2017-VETMED
tions potentially detrimental to the delicate ocular 
setup. The immune system of the eye consists of 
an eye-associated lymphoid tissue (EALT), which 
is a branch of the mucosal immune system (Knop 
and Knop 2007).
Like in the rest of the body, the ocular immune 
system includes both innate and adaptive defences. 
Innate immunity is the first line of defence sustained 
by physical barriers such as blinking, the third eye-
lid and tear film, which contribute to protect the 
eye against microorganisms, chemicals or aller-
gens. Adaptive immunity acts as the second line 
of defence and is promoted by both humoral and 
cell-mediated mechanisms. These two types of im-
munity are in continuous interplay with each other 
in order to ensure appropriate responses to different 
conditions: tolerance of normal microflora, expo-
sure to environmental irritants, limited blood and 
lymph supply of the cornea and high sensitivity of 
ocular tissues to inflammatory responses (Day and 
Crispin 2008; Gilger 2008; de Andrade et al. 2016).
The eye is considered an immunologically privi-
leged site because of its scarcity of resident lympho-
cytes and antigen-presenting cells (APCs), absence 
of lymphatic drainage except of the conjunctival 
type, and the existence of a blood-aqueous barrier 
and a blood-retinal barrier (BRB). Nevertheless, 
the eye is not forsaken by the systemic immune 
system, as demonstrated by the elicitation of a sys-
temic immune response after the introduction of 
an antigenic molecule into the anterior chamber. 
However, in this privileged organ, allografted cells 
may evade immune detection and avoid rejection. 
In other words, immunological processes are tightly 
interrelated in order to achieve a local immunologi-
cal escape, which prevents deleterious intraocular 
reactions (Day and Crispin 2008). A failure of this 
mechanism can cause infectious keratitis or, more 
seriously, immune-mediated disorders (Gilger 2008).
The purpose of this article is to review the exist-
ing literature on canine eye immunology and to 
correlate the immune privilege of the eye with the 
pathogenesis of some ocular diseases.
2. Ocular innate immunity
The innate branch of the immune system is the 
first line of protection against different types of 
insults (microorganisms, allergens, pollutants, 
chemicals and radiation) and it is not specific.
The physical action of eyelid closure (blinking) 
coupled to tear washout effectively hinder micro-
organism invasion and colonization.
The ocular surface is lined with a non-keratinized 
stratified epithelium (basal, middle and superficial 
layers) that contains many mucin-producing goblet 
cells; its superficial layers are in contact with mi-
croorganisms (i.e., the ocular microflora) and act as 
a barrier to microorganism intrusion thanks to the 
presence of epithelial intercellular tight junctions 
and to the rapid regeneration of epithelial cells with 
shedding of the external layers and consequently 
of the potentially infected cells (Lavach et al. 1977; 
Gilger 2008; de Andrade et al. 2016; Galletti et al. 
2017).
The most recent studies have shown that the eye’s 
surface microflora plays a part in both the defence 
of ocular health and in the initiation of diseases, 
in particular by stimulation of immune cells and 
control of mucin synthesis. Different studies have 
uncovered the role of microflora cross talk with pat-
tern recognition receptors in immune protection 
and vision preservation (Miller and Iovieno 2009).
The components of the mucus gel of the tear veil 
help to maintain clarity, cohesion, hydration and 
preservation of the eye’s shallow (Royle et al. 2008). 
The tear film plays the following important roles: 
providing an even surface for light refraction, lu-
bricating the palpebrae as well as the conjunctiva 
and the cornea, providing the latter with nourish-
ment, removing metabolic excretions, allowing 
lymphocytes to reach the cornea and conjunctiva, 
clearing away extraneous substances and protect-
ing the surface of the eye from pathogens by the 
deployment of specific and non-specific molecules 
(Davidson and Kuonen 2004). The canine tear film, 
measuring 7–10 μm (Pinto Ribeiro et al. 2008), in-
cludes an inner mucus film mainly secreted by the 
epithelial cells and the conjunctival goblet cells, 
an intermediate watery layer generated by nicti-
tans and lacrimal glands and an external oily layer 
originating primarily from the Meibomian glands 
(Cabral et al. 2005; Day and Crispin 2008).
The mucus film provides lubrication and protec-
tion of the cornea, binds the watery tear layer to the 
epithelium of the cornea, preserving it from physi-
cal stress, and impedes dryness and microorganism 
spread. The aqueous layer lubricates and protects 
the surface of the eye; it removes external bodies 
from the cornea or conjunctiva, and it harbours 
antiseptic molecules and antibodies. The watery 
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As signified by their name, these molecules have 
the capacity to kill or inhibit the growth of microor-
ganisms; although the single peptides vary in their 
efficiencies in killing different microorganisms, 
as a group they are effective against both Gram-
negative and Gram-positive bacteria, some fungi 
and certain viruses (McDermott 2004; Garreis et al. 
2010). AMPs also have a spectrum of non-microbi-
cidal functions and act as signalling molecules; they 
are immunomodulators, have anti-cancer activity 
and control vascularisation and wound healing 
(Mohammed et al. 2017). Mammalian defensins are 
typically 29- to 45-amino acid molecules containing 
six cysteine residues that are connected to build 
three disulphide bonds and a β-sheet structure. 
They can be distinguished into two groups, known 
as α and β, according to location and interaction 
of the cysteines. During inflammation or infection, 
α-defensins are produced by resident neutrophils, 
while β-defensins are produced by epithelial cells 
(McDermott 2004).
Apart from these AMPs, tears also contain other 
antimicrobial compounds, mainly in the aqueous 
film. For example, lysozyme, a molecule that acts as 
a first line of defence against ocular pathogens, is se-
creted by the tear gland and it induces bacteriolysis 
due to hydrolysis of the peptidoglycan in bacterial 
cell walls. Due to its chitinase activity, lysozyme also 
possesses antifungal effect (Davidson and Kuonen 
2004). Tear glands also produce lactoferrin; this 
molecule reversibly attaches to two atoms of iron, 
hence diminishing the levels of this metal available 
for the metabolism and growth of bacteria. Some 
bacteria hinder the activity of lactoferrin by produc-
ing and exposing proteins that function as lactofer-
rin receptors on their outer membranes. These bind 
and “trap” lactoferrin, allowing the bacteria to use 
the iron attached to it. This capability to chelate 
iron may increase the pathogenicity of some bac-
teria. Furthermore, lactoferrin binds copper, im-
munoglobulins (IgA, IgG) and complement system 
proteins, in this way modulating immune system 
function. The α-lysin molecule (whose source in the 
tear film is not known) induces cell membranes to 
rupture by an as yet uncharacterised mechanism. 
The content of α-lysin in tears is higher than in 
plasma, serum or aqueous humour. Complement is 
discharged from the serum and participates in bac-
terial lysis (Davidson and Kuonen 2004; Knop and 
Knop 2007; Garreis et al. 2010). Finally, tear-specific 
prealbumin (lipocalin) scavenges potentially harm-
film also contains dispersed mucin (that lowers 
the superficial tension, increases the diffusion of 
the aqueous layer and confers viscosity to the tear 
film), lactoferrin, lysozyme, transferrin, tear-spe-
cific prealbumin, albumin, ceruloplasmin, glyco-
proteins and immunoglobulins, which take part in 
the defence of the eye surface. The outermost oily 
Meibomian layer ensures an even optical shallow, 
prevents the dehydration of tears and reduces the 
spread of debris (Davidson and Kuonen 2004).
Mucins present on the ocular surface constitute 
the macromolecular scaffold of this hydrated gel, 
and glycans decorate these glycoproteins represent-
ing an abundant source of binding ligands. Both of 
these molecules control microbial binding, prevent 
bacterial colonisation, contribute to eliminating 
surface foreign material and modulate the physico-
chemical peculiarities of the gel (Royle et al. 2008). 
Furthermore, the transmembrane mucins dock the 
ocular tear veil to the external corneal epithelium 
allowing the transition between aqueous tear film 
and hydrophobic epithelium (Gilger 2008). Mucins 
of the natural tear film are mostly uncharacterised, 
but in dogs two different types of mucins, secreted 
and membrane-bound, have been identified; the 
gel layer of this pre-ocular tear film seems to have 
peculiar features which differentiate it from other 
supramucosal layers (Hicks et al. 1997). The major 
structural difference between the human and ca-
nine ocular glycans is that sialylated glycans prevail 
in human, while fucosylated glycans predominate 
in dogs (Royle et al. 2008). The synthesis and se-
cretion of mucin by goblet cells are induced by dif-
ferent cytokines (e.g., IL-6 and IFN-γ) released by 
dendritic cells and inflamed conjunctival cells and 
are crucial in preserving eye health. In the past, 
tear supply and control of the inflammation of the 
ocular surface were the main treatments for dry 
eye syndrome (keratoconjunctivitis sicca, see be-
low). Drug-based modulation of mucin secretion 
is now an additional therapeutic option for dry eye 
syndrome characterized by unstable tear layer, and 
has the advantage of sustaining a healthy tear layer 
formulation (Kim 2015).
Tear film and anatomical barriers of the eye 
surface (mucous and epithelium) contain several 
antimicrobial peptides (AMPs). These molecules 
are synthesised by epithelial cells of the cornea, 
conjunctiva, lacrimal sac and nasolacrimal surface, 
and they contribute to the prevention of microor-
ganism invasion (Haynes et al. 1999; Gilger 2008). 
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ful bacterial molecules, and angiogenin, a lacrimal 
protein highly concentrated in tears, has mainly 
microbicidal activity in the tear layer (Paulsen et 
al. 2005; Knop and Knop 2007; Gilger 2008).
Toll-like receptors (TLRs) are innate immune 
receptors that sense the presence of microorgan-
isms. They are normally expressed on cells that are 
most likely to initially encounter microbes, such 
as dendritic cells, mast cells, neutrophils and mac-
rophages (Gilger 2008). Epithelial surface cells of 
the cornea lack expression of surface TLRs; they are 
mainly intracellular or exposed by the basal epithe-
lial cells, thereby impeding pathogen recognition 
by TLRs (Ueta et al. 2004). TLRs are transmem-
brane proteins with an extracellular domain which 
binds to the ligand (pathogen-associated molecular 
pattern, PAMP), a transmembrane domain and an 
intracellular domain which transduces the signal 
through a cascade resulting in the production of 
pro-inflammatory cytokines. In this way, TLRs also 
play a crucial role in stimulating inflammation and 
in eliciting and modulating the adaptive immune 
response. Different invaders (bacteria, viruses, fungi 
and also worms) can harbour PAMPs and stimu-
late ocular TLRs (Chang et al. 2006; Turin and Riva 
2008). The response of TLRs to PAMPs depends on 
the specific receptor and cell type and can include 
microbial phagocytosis, reactive nitrogen and oxy-
gen species production, inflammatory cytokine syn-
thesis and expression of co-stimulatory molecules 
(Gilger 2008). TLRs play an important role in the 
immune response of the ocular surface, in particu-
lar by facilitating the interplay between the innate 
and adaptive immune responses; they promote the 
immunological tolerance of the ocular surface to 
environmental antigens in order to hinder need-
less inflammatory responses to normal flora (the 
so-called “immunosilent condition”) (Ueta et al. 
2004; Gilger 2008). Moreover, the ocular surface is 
characterised by a shift to a pro-inflammatory envi-
ronment when the eye is closed. Indeed, the closure 
of the eyelids during sleep markedly decreases oxy-
gen exchange and tear secretion; the complement 
in tears increases during the first hours of sleep, 
and many neutrophils reach the site; furthermore, 
hypoxia increases the synthesis of TLRs in conjunc-
tival epithelium, and blinking causes exfoliation of 
corneal cells, which subsequently ends (Sack et al. 
2000; Galletti et al. 2017).
Nuclear-binding oligomerisation domain (NOD) 
proteins are cytoplasmic signalling receptors of 
the innate immune system that sense intracellular 
pathogens by recognising their PAMPs. Similar to 
TLRs, the binding of the ligand to NOD proteins 
triggers the stimulation of the transcription factor 
nuclear factor-κβ, which induces the transcription 
of pro-inflammatory cytokine genes. NOD proteins 
(NOD1 and NOD2) are expressed in canine basal 
corneal epithelium, corneal endothelium and con-
junctival epithelium but not in goblet cells. The 
presence of NOD proteins at the barrier regions 
of the eye suggests a role in the detection of ocular 
germs and the induction of antimicrobial defences 
(Scurrell et al. 2009).
3. Ocular adaptive immunity
The immune components of the eye surface are 
known as eye-associated lymphoid tissue (EALT), 
which is part of the mucosa-associated lymphoid 
tissues (MALT). EALT represents a functional mu-
cosal immunological system consisting of lacrimal 
glands, lacrimal drainage-associated lymphoid tis-
sue and conjunctiva-associated lymphoid tissue. 
MALT and hence EALT have peculiarities that dif-
ferentiate them from the components of the cen-
tral immune system. In particular, immunological 
tolerance, ignorance or immunosuppression of the 
peripheral microenvironment abrogate reactivity 
and induce anti-inflammatory immune responses 
(Knop and Knop 2005a; Knop and Knop 2007). On 
the other hand, the eye should maintain the ability 
to effectively respond to multiple invaders.
EALT (as well as MALT) includes two types of 
structures, an “organised” lymphoid tissue made 
of immune cells organised in follicles, and a vast 
“diffuse” lymphoid tissue. The follicular organised 
form serves as an afferent branch of mucosal im-
munity, since antigenic molecules are captured 
from the environment by the specialised overly-
ing follicle-associated epithelium, processed by 
antigen-presenting cells and presented to lympho-
cytes, which are activated and then proliferate and 
differentiate into effector cells (T or B lineage) and 
finally migrate from follicles to afferent lymphatic 
vessels, the bloodstream and effector organs (lac-
rimal gland and conjunctiva). Conversely, the dif-
fuse form of lymphoid tissue serves as an efferent 
branch of mucosal immunity and it includes the 
arising effector cells delivered via post-capillary 
blood vessels that are diffused throughout the mu-
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cosae and the associated glands. Lymphoid cells are 
found in the connective tissue as lamina propria 
lymphocytes and plasma cells or within the ba-
sal layers of the epithelium as intraepithelial lym-
phocytes, while effector cytotoxic T lymphocytes 
(CTLs) are found in the epithelium, where they are 
more abundant than T helper lymphocytes, whose 
role is to modulate the differentiation of other cells 
(Knop and Knop 2005a; Knop and Knop 2005b; 
Knop and Knop 2007; Gilger 2008). Studies on the 
localisation of EALT in the conjunctiva demon-
strated its presence in the superficial top of the 
cornea, particularly when the eye is shut. This 
localisation, along with the fact that the cornea 
lacks its own lymphoid cells, and the fact that in 
the shut-eye situation (e.g. during night-time) the 
corneal integrity is preserved by a large influx of 
leukocytes and their mediators, strongly suggests a 
crucial role for EALT in maintaining corneal health 
and integrity (Knop and Knop 2005b).
The function of the lymphocytes in the eye sur-
face is not to induce inflammation but, on the con-
trary, to inhibit inflammatory processes which may 
cause destruction of the ocular surface tissue. The 
activation and modulation of the mucosal immune 
response is controlled via antigen presentation by 
different types of APCs and is carried out by vari-
ous populations of effector T helper lymphocytes 
resulting from this priming process (Dana 2004; 
Knop and Knop 2005b).
3.1 APCs, lymphocytes and plasma cells
Similar to the innate immune response, the ac-
quired immune response branches out into cell-
mediated defence, which is directly operated by 
T lymphocytes, and humoral defence, which is 
sustained by soluble antigen receptors (immuno-
globulins) produced by plasma cells of the mucosa. 
In contrast to innate immunity, acquired immunity 
involves lymphoid cells, and it is more specific and 
variable (Knop and Knop 2007). This antigen-specif-
ic second line of defence is characterised by memory, 
and therefore it reacts more rapidly upon subsequent 
exposure to the same antigen (Gilger 2008).
In eye immunology, there is an “afferent” immu-
nological pathway of antigen capture, processing 
and presentation and an “efferent” immunological 
pathway of diffusion and activity of effector cells; 
in the middle is antigen recognition and presenta-
tion, which connects innate and adaptive immunity 
(Knop and Knop 2007).
The adaptive immune system of the eye includes 
APCs, different cytokine-secreting T lymphocytes 
(cell-mediated immune response) and antibody-
secreting B lymphocytes once they have become 
plasma cells (humoral immune response) (Gilger 
2008).
3.1.1 The ocular APCs
The APCs process the antigen and display its 
epitopes complexed with the major histocompatibil-
ity complex (MHC) class II (MHC-II) molecules on 
their surface (in a process known as “antigen presen-
tation”) and then migrate via draining lymph nodes 
to prime naïve T helper lymphocytes. These cells 
constitutively express MHC-II, and APCs are con-
sidered “professional” if they express high levels of 
the MHC-II tetramer and co-stimulatory molecules 
and thus efficiently prime T lymphocytes. This is the 
case of macrophages, dendritic cells (DCs), B lym-
phocytes and epithelial Langerhans cells (LCs); the 
latter are found in the epithelial layer of the periph-
eral cornea, but they are not present in the central 
cornea; this is considered the main reason for cor-
neal immune privilege (see below). However, during 
inflammatory processes (e.g., infectious keratitis), 
APCs are attracted to the cornea from the limbus 
after infiltration of neutrophils and macrophages 
and after release of cytokines (particularly IL-1 and 
TNF-α). Conversely, “nonprofessional” APCs are 
characterized by a low potential to stimulate T lym-
phocytes as a result of low constitutive expression 
of MHC-II and co-stimulatory molecules; nonethe-
less, under some conditions (e.g., inflammation) 
they may also produce signals capable of priming 
T lymphocytes. Vascular endothelial and some mes-
enchymal cells, for example, are nonprofessional 
APCs with stimulatory potential. As in other tissues, 
the most potent APCs on the ocular surface are DCs 
and LCs. Corneal LCs are bone marrow-derived 
cells similar to skin LCs. Under healthy conditions, 
LCs are the only cells that constitutively express the 
MHC-II tetramer in the corneal epithelium and skin 
(Dana 2004; Gilger 2008).
During the last years, the search for corneal APCs 
based on their MHC-II expression has resulted 
in the conclusion that the normal central cornea 
lacks APCs, although MHC-II-positive cells have 
6Review Article Veterinarni Medicina, 64, 2019 (01): 1–17
https://doi.org/10.17221/137/2017-VETMED
occasionally been found. Even without these cells, 
multiple corneal stimuli (e.g., trauma, infection) 
are capable of inducing migration of LC from the 
limbus to the cornea. The normal uninflamed cor-
nea is indeed equipped with numerous immature 
MHC-II-negative LC-type DCs. Conversely, the in-
flamed cornea harbours activated LCs that express 
high levels of MHC-II and co-stimulatory molecules 
(Hamrah et al. 2002). It has recently been shown 
that the normal corneal epithelium is characterised 
by CD11c+ Langerin+ cells that are LCs, while the 
stroma is equipped with a different population of 
(non-LC) Langerin+ DCs. Langerin is a c-type lectin 
produced by specialised DCs, and it senses glyco-
sylated patterns on pathogenic microorganisms (e.g., 
mycobacteria). In the past, Langerin was thought to 
be expressed uniquely by Langerhans cells. Recently, 
however, DC (CD11c+) populations other than LCs 
were detected that are able to produce Langerin (the 
so-called “(non-LC) Langerin+ DCs”); these cells 
have been described to be present in the dermis, 
lung, gut, kidney, liver and now in the ocular cornea 
too (Hattori et al. 2011). The central cornea is indeed 
populated by heterogeneous epithelial and stromal 
DCs, which act as APCs. While the corneal periph-
ery includes immature and mature resident bone 
marrow-derived CD11c+ DCs, the central cornea 
contains only immature and precursor DCs, both 
in epithelium and stroma, where Langerhans cells 
and monocytic DCs are located, respectively. When 
inflammation occurs, most resident DCs undergo 
maturation and overexpress MHC-II and B7 (CD80/
CD86) co-stimulatory molecules. Besides DCs, mac-
rophages are also found in the posterior corneal stro-
ma. These observations modified the thesis that the 
cornea is immune-privileged because of the absence 
of resident lymphoreticular cells and indicate that 
cornea is equipped with different cellular mecha-
nisms for antigen presentation (Hamrah et al. 2003).
All epithelial layers of the canine cornea harbour 
CD45+ and CD11c+ immunocompetent DCs. These 
are more numerous at the periphery and their num-
bers diminish when moving towards the central 
area; these cells appear to be inactive since they 
do not express MHC-II. Their presence all over 
the corneal epithelium may represent an effective 
mechanism to inhibit or resolve inflammatory 
diseases caused by microorganisms on the ocular 
surface (Carvalho et al. 2009).
Investigations over the past decade have added 
to our knowledge of the cellular components of the 
mononuclear phagocyte system (MPS), which com-
prises DCs, monocytes and macrophages, but MPS 
functionality is still an open question. The tissue-
specific activation of MPS cells which stimulate the 
acquired immune response is strictly regulated, and 
immune-privileged site is poorly understood. It is 
likely that MPS has different ways of triggering ac-
quired immune reactions in the immune-privileged 
environment of eye. Evidence suggests that lym-
phangiogenesis in the cornea improves the migra-
tion of antigen-laden DCs to the lymph nodes and 
consequently amplifies the T lymphocyte responses. 
In addition, some corneal nerves can produce neu-
ropeptides that block corneal immune privilege and 
allow stimulation of T lymphocytes. Moreover, com-
mensal-derived antigens from non-privileged distal 
sites may trigger the stimulation of T lymphocytes, 
which subsequently target host cells in immune-priv-
ileged tissues. Finally, germs can activate immune 
reactions via innate lymphoid cells or via γδ T lym-
phocytes, and gut commensal microorganisms can 
alter the central nervous system (CNS) by disturbing 
the functionality of microglia (Reyes et al. 2017).
3.1.2 Cell-mediated immunity: immune 
tolerance or inflammatory response?
Ocular surface APCs migrate towards the drain-
ing lymphoid compartments and stimulate naïve T 
cells, which consequently peripheralise and home 
in to the ocular surface. Evidence suggests that 
regulatory T cells (Treg) play an important role in 
limiting immune damage caused by autoreactive 
T lymphocytes (Barabino et al. 2012). Antigen 
presentation in the absence of co-stimulation 
leads to anergy or disappearance of the reactive T 
lymphocytes or appearance of functional immu-
nosuppressive Treg lymphocytes, both resulting in 
non-reactivity (immune tolerance) (Knop and Knop 
2007). Tolerance is evoked towards the multitude of 
non-pathogenic environmental antigens that reach 
the ocular surface and it is triggered by Tregs via the 
expression of immunosuppressive cytokines such 
as IL-10 and TGF-β. Tolerance should, of course, 
also be sustained versus the body’s own tissue an-
tigens (Knop and Knop 2005a).
Co-stimulation in the presence of IL-4 directs T 
helper (TH) lymphocytes towards TH2 cells, which 
synthesise IL-4 and IL-5 cytokines that subsequent-
ly trigger the differentiation of antibody-producing 
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plasma cells normally producing anti-inflammatory 
IgA. When other immunoglobulin isotypes (e.g. 
IgE) are generated, allergic diseases may arise. 
Co-stimulation in the presence of IL-12 results in 
TH1 cells that synthesise inflammatory cytokines 
(e.g. IFN-γ, TNF-α) and trigger an inflammatory 
reaction potentially harmful to the surface of the 
eye. The presence of antigens from pathogenic 
microorganisms usually leads TH1 lymphocytes to 
mount an inflammatory cellular response, because 
the potential tissue destruction that may occur is 
preferable to the risk of infection (Knop and Knop 
2005a; Knop and Knop 2007).
In follicles, the antigen is presented by APCs to 
naïve lymphocytes; subsequently, the lymphocytes 
undergo proliferation, activation and differentia-
tion into effector cells (e.g., B or T lymphocytes). 
Primed lymphocytes migrate to the bloodstream 
and to effector organs such as lacrimal glands 
and conjunctiva. Diffuse lymphoid tissue (intra-
epithelial lymphocytes and plasma cells) is inter-
spersed along the lacrimal gland and conjunctiva. 
Lymphocytes are primarily cytotoxic T cells; a few 
are T helper cells. Plasma cells are implicated in 
secretory immunity through synthesis of specific 
antibodies (e.g., IgA), which cross the overlaying 
epithelium and are liberated in the tear film and 
ocular surface (see below) (Knop and Knop 2005a).
3.1.3 Humoral immunity: secretory IgA and 
other immunoglobulins
Plasma cells in mucosal tissues are crucial for 
the synthesis of specific immunoglobulins (most-
ly IgA), which cross the overlying epithelium and 
form a surface layer of secretory IgA. In dogs, 
IgA-secreting plasma cells predominate in lac-
rimal glands and conjunctiva, and secretory IgA 
is released into the tear film and ocular surface 
(Gilger 2008). The secretory component protects 
them from the proteolysis carried out by lacrimal 
enzymes (Schlegel et al. 2003). The secretion of 
IgA by lacrimal tissue is controlled by immune fac-
tors, hormones and neural networks (Davidson and 
Kuonen 2004; de Andrade et al. 2016).
Secretory IgA molecules protect the eye from bac-
terial adsorption and colonisation, viral infection 
and parasite infestation (Sullivan 2000; Davidson 
and Kuonen 2004) by coating microorganisms and 
therefore impeding their attachment to the corneal 
epithelium and by promoting bacterial agglutina-
tion, antimicrobial neutralisation and lysis. IgA is 
dispersed in tears as a soluble glycoprotein or linked 
to eye mucus. IgG molecules are normally present 
at very low concentrations in tears; their levels are 
increased during inflammation and they take part 
in phagocytosis and complement-mediated bacte-
rial lysis. IgM molecules are expressed in tears too, 
at very low concentrations (Davidson and Kuonen 
2004). In dogs, as in humans, IgA is the prevalent 
Ig in tears, followed by IgG and IgM, with large 
variations in concentrations between individual 
dogs (German et al. 1998; Day and Crispin 2008).
The concentration of albumin in tears signifi-
cantly correlates with IgG, but not with IgM or IgA; 
IgM and IgA concentrations in tears correlate with 
each other. These relationships hint at a similar 
passage for IgG and albumin into secretions and 
a different one for IgM and IgA. Because albumin 
passively diffuses from serum into secretions, se-
rum is presumably also the source of IgG found in 
mucosal secretions. Conversely, IgM and IgA are 
synthesised and secreted by the plasma cells of local 
glandular tissue (German et al. 1998).
3.2 The retina and its immunity
The retina is the third and inner ocular coat (after 
the cornea and lens); it is a highly specialised tis-
sue crucial for vision. Injury to any of the sophis-
ticated components of the retina may cause visual 
loss (Detrick and Hooks 2010). The retina contains 
several types of immune cells, most of which rep-
resent the so-called “glia”, which are particularly 
sensitive and easily activated after infection or 
injury (Garden and Moller 2006). Furthermore, a 
particular structure, the retinal pigment epithe-
lium (RPE), plays a crucial role in defending the 
eye (Detrick and Hooks 2010).
3.2.1 The glia cells
Three kinds of glial cells are primarily found in 
the mammalian retina, where they contribute to 
maintaining homeostasis: Müller cells (the preva-
lent ones), astrocytes and microglia (Vecino et al. 
2016). A fourth type of glial cells, the oligodendro-
cytes, is found only sporadically in the retina in 
association with myelinated ganglion cell axons in 
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the nerve fibre layer of a few animal species (Fischer 
et al. 2010; Vecino et al. 2016).
Glial cells maintain structure, contribute to me-
tabolism and potassium uptake, perform phago-
cytosis of neuronal debris and produce particular 
transmitters and trophic stimuli. Astrocytes reside 
mainly in the nerve fibre layer and their processes, 
similar to Müller cells, envelope the blood vessels 
creating the BRB; they also perform a crucial func-
tion in ion homeostasis. In addition, microglia can 
be triggered to function as macrophages, and can 
interact with neurons and other glial cells via pro-
duction of growth factors. The secretion of IFN-γ 
by infiltrating stimulated T lymphocytes first trig-
gers Müller cells, astrocytes and microglial cells to 
synthesise class I and class II MHC molecules and 
prime these cells for further cytokine expression; 
the final result is initiation and/or spread of im-
mune reactions. The intrinsic signalling pathways 
of glial cells propagate through Ca2+ waves (cor-
related with glutamate release). These cells play a 
crucial role in immunity, neuroprotection and an-
giogenesis. In the case of malfunction, they become 
primary pathogenic factors, and then the neuroglia 
responds to injury in order to restore homeostasis 
(Genini et al. 2014; Vecino et al. 2016).
Similar to astrocytes, Müller cells are capable 
of wrapping around axons and of forming glial 
connections between the retina and blood vessels 
(Hollander et al. 1991). Moreover, both Müller cells 
and astrocytes contribute to the glial sheaths sur-
rounding neurons. In dogs, retinal axons are packed 
and interposed between the end-feet of the Müller 
cells in nest-like systems (Vecino et al. 2016). The 
“strategic” location of Müller cells makes them a 
structural and functional connection between the 
retinal neurons and the compartments with which 
they interchange molecules (sub-retinal space, 
retinal blood vessels and vitreous chamber), ful-
filling the important roles of promoting neuronal 
development, survival and the relay of information 
(Reichenbach and Bringmann 2010; Vecino et al. 
2016).
Astrocytes are mostly present only in the deepest 
retinal layers where they provide structural support 
for degenerating axons, neurotrophic supplements 
and sustain the BRB. As a reaction to disease or 
damage, the astrocytes produce proteins that jeop-
ardise the integrity of the BRB via up-regulation 
of the expression of genes coding for cytokines, 
chemokines and complement cascade elements, 
which contribute to retinal degeneration (Kim et 
al. 2006; Vecino et al. 2016).
The CNS immune privilege (see below) was 
thought to be linked to the presence of the blood-
brain barrier and the lack of lymph or of tissue-
resident competent macrophages. The most recent 
studies have provided evidence of robust interac-
tions between the immune system and the CNS and 
proved that microglia play a crucial role in regulat-
ing immune functions (Carson et al. 2006; Vecino 
et al. 2016). The CNS responds through both innate 
and adaptive immune reactions involving different 
populations of immune-competent cells such as mi-
croglia, astrocytes, macrophages and infiltrating T 
lymphocytes, which communicate by direct contact 
or by paracrine signals (Colton 2009; Ransohoff and 
Brown 2012; Corraliza 2014; Vecino et al. 2016). 
Reactivity of microglia is considered a symptom 
of different retinal inflammatory and degenerative 
diseases (Karlstetter et al. 2015). Microglia include 
local macrophages of the CNS, which carry out im-
mune functions and contribute to the development 
and sustenance of the neural network and tissue ho-
meostasis (Ransohoff and Brown 2012; Fernandes 
et al. 2014; Gertig and Hanisch 2014; Vecino et al. 
2016; Reyes et al. 2017). Resident microglial cells 
act as immunological “watchdogs” of the retina and 
brain. They sense the neuronal microsurroundings 
and quickly react to stimuli by turning into acti-
vated phagocytes (Karlstetter et al. 2015). Microglia 
interact with different resident cells and neurons 
by secreting cytokines and chemokines (defined as 
their secretome) that represent signature factors 
for certain functional or pathological states (e.g. 
reactive oxygen species, nitric oxide, brain-derived 
neurotrophic factor, phospholipase A2 IIA type, 
insulin-like growth factor, glial cell line-derived 
neurotrophic factor, fibroblast growth factor 2 and 
lipocortin 1; Jha et al. 2013; Vecino et al. 2016). 
Canine retinal microglia also enagages in phago-
cytosis and reactive oxygen species production and 
exhibits the characteristic CD11bhigh CD45low im-
munophenotype (Genini et al. 2014).
3.2.2 The retinal pigment epithelium 
The retinal pigment epithelium is a cellular mon-
olayer inserted between the blood-rich choroid and 
the photoreceptor layer. The latter and the RPE are 
necessary for vision. RPE cells accomplish multi-
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ple functions that are physiologically important 
to sustain the neural retina (Bok 1993) and im-
munologically important in the immune defence. 
Indeed, the RPE cells synthesise TLRs (1–7, 9 and 
10 (Kumar et al. 2004)), complement proteins and 
Fc-γ receptors; they react to IFN-γ administration 
and up-regulate the synthesis of both MHC class 
I and II molecules, and they serve as local retinal 
APCs. Moreover, these cells produce proinflamma-
tory cytokines (IL-6, IL-8, and MCP-1), chemokines 
and growth factors, which play an important role 
in pathological processes. Nonetheless, the eye is 
also equipped with systems capable of suppressing 
immune reactions (e.g., TGF-β, IL-11 and IFN-β). 
Finally, dysfunction or damage of RPE cells may re-
sult in ocular pathologies (Detrick and Hooks 2010).
4. Ocular immunity in the elderly
In the elderly, the body tends to lose many ho-
meostatic mechanisms. Susceptibility to infection, 
neoplasia and autoimmunity is enhanced due to 
debilitation or dysregulation of the immune sys-
tem and loss of immune privilege (Dorshkind et 
al. 2009; Forrester and Xu 2012). These changes 
(“immunosenescence”) involve both systemic and 
mucosal compartments, as well as both innate and 
adaptive immunity in humans (Shaw et al. 2013; 
Mashaghi et al. 2017) and in dogs (Strasser et al. 
2000; Blount et al. 2005). The benefit of vaccina-
tion in preventing infectious diseases is hampered 
both in aged humans (Goronzy and Weyand 2013) 
and dogs (HogenEsch et al. 2004), mainly because 
of an inability to maintain long-lasting adaptive 
immunity.
Also, the defence mechanisms of the eye (tear 
layer, lacrimal and Meibomian glands, corneal and 
conjunctival epithelia) are impaired with aging. 
Furthermore, a breakdown of the immunological 
balance of resident corneal APCs, Tregs and T help-
er 1 cells (TH1) in the elderly can cause dysfunc-
tion of the eye and impaired vision (Mashaghi et 
al. 2017). Therefore, immunosenescence is associ-
ated with a number of ocular pathologies, including 
increased occurrence of bacterial, viral and fun-
gal conjunctivitis and keratitis, higher frequency 
of some neoplasia (e.g., limbal melanoma, eyelid 
squamous cell carcinoma; da Conceicao et al. 2010) 
and local immune-mediated diseases or complica-
tions of systemic autoimmunity.
5. Ocular immune privilege
The ocular anterior chamber is characterised by a 
unique immune reaction system, referred to as “im-
mune privilege”. This special immunologic status 
promotes tolerance of foreign antigens in order to 
avoid an enormous immune response. The “story” 
of immune privilege begins in 1873 with the find-
ings of the Dutch ophthalmologist van Dooremaal, 
who inserted various extraneous objects and tissues 
into the eyes of rabbits and dogs with the aim of 
identifying the aetiology of cataracts. He did not 
uncover the cause of cataracts, but he noticed an 
extended survival of mouse skin grafts implant-
ed into the ocular anterior chamber of the dog 
(Van Dooremaal 1873). Seventy-five years later, 
the British biologist Medawar “rediscovered” the 
protracted survival of extraneous tissue grafts in-
serted into the ocular anterior chamber of rabbits 
and proposed the term “immune privilege” for 
this phenomenon (Medawar 1948). The apparent 
lack of lymphatic drainage in the anterior chamber 
was considered responsible for the antigen trap-
ping in the eye, resulting in the phenomenon of 
“immunological ignorance”. For the discovery of 
acquired immunological tolerance, Medawar (and 
his colleague Burnet) shared the Nobel prize in 
Physiology or Medicine 1960 (www.nobelprize.
org/nobel_prizes/medicine/laureates/1960/). In 
the late 1970s, Kaplan and Streilein observed that 
antigens inserted into the ocular anterior chamber 
not only reached the peripheral lymphoid tissues 
but also stimulated a systemic downregulation of 
antigen-specific cell-mediated immune reactions 
(Kaplan and Streilein 1977; Kaplan and Streilein 
1978), a phenomenon subsequently termed anteri-
or chamber-associated immune deviation (ACAID) 
(Streilein and Niederkorn 1981). ACAID plays a 
crucial role in protecting the ocular anterior cham-
ber from antigenic stimulation and uncontrolled 
inflammatory response (Streilein 1990). A similar 
immune deviation occurs also in the brain and it 
is known as “brain-induced immune deviation”. In 
this case, similar to ACAID, the CNS is neither 
disconnected nor inert in its interplay with the 
immune system; indeed, local immune cells can 
pass through the intact blood-brain barrier, and 
CNS neurons and glia stimulate lymphocyte and 
macrophage reactions (Carson et al. 2006).
Generally, immune privilege results from various 
immune regulatory, anatomical and physiological 
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mechanisms that protect vulnerable and vital tissues 
or organs (such as the eye) with a very limited re-
generative capacity (Niederkorn 2002; Niederkorn 
2012).
First of all, physical barriers such as the blood-
aqueous barrier and the lack of efferent lymphatic 
vessels prevent the passage of large molecules and 
cells into and out of the eye (Zhou and Caspi 2010). 
The cornea itself is considered an immune-privi-
leged site as a result of multiple active and passive 
mechanisms involving both innate and acquired im-
munity. The lack of TLRs on the epithelial surface 
of cornea cells is primarily responsible for minimis-
ing antigen recognition (impaired innate immunity) 
(Ueta et al. 2004). Moreover, the scarcity of corneal 
vasculature and lymphatic tissue makes it natural-
ly non-responsive (impaired adaptive immunity) 
(Knop and Knop 2005a). Soluble and cell-bound 
immunosuppressive agents of the ocular microen-
vironment (e.g., neuropeptides, TGF-β, Fas-ligand, 
vasoactive intestinal peptide and others) inhibit 
the activity of immune-competent cells (Zhou and 
Caspi 2010). For example, TGF-β and macrophage 
migration inhibitory factor are present in the aque-
ous humour at concentrations sufficient to inhibit 
natural killer cell-mediated cytotoxicity. This is very 
important, as both corneal endothelial cells and lens 
epithelial cells synthesise little or no MHC class I 
antigen presentation molecules and thus are high-
ly sensitive to natural killer-mediated lysis (Apte 
et al. 1998; Niederkorn 2006). Besides inhibiting 
T lymphocytes, the RPE and the iris/ciliary body 
also triggers them to turn into Treg lymphocytes. 
Lastly, the eye actively modulates systemic immune 
responses, as for example in ACAID (Streilein 2003; 
Caspi 2006; Caspi 2008; Caspi 2010; Zhou and Caspi 
2010; Perez et al. 2013; de Andrade et al. 2016).
After inoculation into the anterior chamber, solu-
ble antigens are locally processed by mechanisms 
controlled by intraocular cytokines such as TGF-β 
and then translocated via the bloodstream to the 
spleen (ACAID does not occur in absence of spleen) 
(Streilein 2003; Day and Crispin 2008). In this case, 
the humoral immune response is favoured, along 
with a simultaneous inhibition of the delayed type 
hypersensitivity reaction together with preferred 
stimulation of TH2 cells or IL-10-producing Treg 
lymphocytes. If cell-associated antigens are inocu-
lated into the anterior chamber, a different form of 
ACAID occurs. Helper and cytotoxic T lympho-
cytes are stimulated, and they recirculate to the 
inoculated eye (penetrating via the uveal tract); 
however, they do not undergo functional differ-
entiation, presumably because of local activity of 
TGF-β (Day and Crispin 2008). Alternatively, they 
synthetize Fas, which binds to Fas-ligand, ubiqui-
tously expressed in the ocular cells (e.g. cornea, 
iris, ciliary body and retina), and induce apoptosis. 
The synthesis of Fas-ligand is considered helpful 
in creating a barrier which encompasses the eye 
and protects it from the activity of inflammatory 
cells (expressing Fas) that are recruited into the 
eye (Griffith et al. 1995; Day and Crispin 2008; de 
Andrade et al. 2016).
Programmed death receptor-1 (PD-1 or CD279) 
and its ligand PDL-1 belong to the B7/CD28 family 
expressed by helper and cytotoxic T lymphocytes as 
well as by natural killer cells and APCs. The binding 
of PD-1 to its ligand (PDL-1) induces suppression 
of T lymphocyte activation, proliferation and cy-
tokine secretion due to alteration of T cell receptor 
signalling. Therefore, these molecules play a crucial 
role in sustaining local tolerance and in preserving 
immune-privileged microenvironments, including 
the ocular one (Coy et al. 2017; Wang et al. 2017).
Whenever these mechanisms are impaired due to 
different causes (e.g., injury of the surface epithe-
lium, decrease of IgA or of the production of immu-
nosuppressive molecules), inflammatory cytokines 
are expressed and the immune system is granted 
uncontrolled access to the antigen (Gilger 2008).
6. Ocular immunity in disease
Both microbial antigens and “danger signals” such 
as tissue disruption or an altered cytokine milieu 
can bias the normal way of antigen presentation 
towards inflammation and, therefore, alteration of 
the physiologically protective mucosal immunity 
(Knop and Knop 2005a). Mechanical destruction 
and increased production of inflammatory cy-
tokines is characteristic, for instance, of several 
types of conjunctivitis and keratoconjunctivitis as 
well as uveitis both in humans and in dogs. Below, 
we briefly describe some examples of immune-
mediated ocular diseases.
Keratoconjunctivitis sicca (KCS), also known as 
“dry eye disease”, is a common syndrome caused 
by a deficiency in the aqueous tear layer due to the 
damage of the lacrimal and the nictitans glands. 
Besides quantitative, also qualitative defects of 
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the tear film result in KCS. Mucin abnormalities 
include mucus accumulation, altered pathways of 
mucus secretion, diminished conjunctival goblet 
cell frequency and aberrant mucin glycosylation 
(Davidson and Kuonen 2004). In the conjunctival 
epithelium of canine patients with KCS, the pop-
ulation of goblet cells is significantly decreased, 
and in the lacrimal glands there is a lymphocyte 
infiltration, mainly by B and T helper lymphocytes 
(Izci et al. 2015). KCS may occur as a secondary 
effect of periorbital (lacrimal) injury, reaction to 
drugs (especially sulphonamides) or acute lacrimal 
inflammation; nevertheless, more frequently it is 
the result of infiltration of lymphocytes into the 
lacrimal gland, followed by atrophy and fibrosis. 
These features are similar to the ones involved in 
the human ocular autoimmune disease, Sjögren’s 
syndrome. Genetic predisposition to KCS is re-
ported for the English Bulldog, Lhasa Apso, Shih 
Tzu and West Highland White Terrier (Day and 
Crispin 2008). KCS is associated with mucoid to 
mucopurulent discharge, blepharitis, discomfort, 
superficial keratitis and, in chronic severe cases, 
abnormal dryness (xerosis), corneal ulcers and 
blindness. Due to these abnormalities, the eye sur-
face may be prone to infections; indeed, dogs with 
KCS allow faster growth of microorganisms (mainly 
coagulase-positive Staphylococcus species and beta 
haemolytic Streptococci, besides Pseudomonas 
species) compared to normal dogs (Davidson and 
Kuonen 2004; Day and Crispin 2008).
Chronic superficial keratitis/keratoconjunctivi-
tis (CSK/CSKC), also known as corneal pannus or 
Überreiter’s syndrome, is another immune-medi-
ated disease of the canine cornea. CSK/CSKC is a 
chronic, generally bilateral, non-ulcerative, prolif-
erative stromal keratitis, prevalent in middle-aged 
German Shepherd dogs. Inflammatory cell infiltra-
tion is carried out by helper (and some cytotoxic) 
T cells, which produce IFN-γ, macrophages and 
plasma cells. Hyperplasia and pigmentation of 
the corneal epithelium are typical consequences. 
Cells from corneal epithelium synthesize MHC-II 
molecules; often, a diffuse sedimentation of IgG 
in the superficial stroma of the limbal conjunctiva 
it is observed, and sometimes in the superficial 
stroma of cornea or in the basement membrane 
of the corneal epithelium. An immune-mediated 
pathology is suggested, since an autoimmune reac-
tion to corneal antigens is involved. The clinical 
sign is corneal opacity caused by surface stromal 
inflammation, vascularisation and fibrosis (Day 
and Crispin 2008).
Both KCS and CSK/CSKC are characterised by 
expression of MHC-II and co-stimulatory signals 
(e.g., adhesion molecule ICAM-1 and CD40) on 
epithelial cells; therefore, they have the potential 
to present self antigens. The T lymphocytes in 
turn produce inflammatory cytokines, creating a 
vicious cycle of increased lymphocyte activation 
and subsequent increased inflammatory cytokines 
in the tissue and tear film, which leads finally to 
alteration of the normal cytokine milieu (Knop and 
Knop 2005a).
Production of inflammatory cytokines by the al-
tered epithelial cells also occurs in ocular allergy. 
Allergic conjunctivitis is the most frequent form of 
human ocular allergy; it is a complex of hypersen-
sitivity diseases, which affect the lid, conjunctiva 
and/or cornea. Symptoms include severe eczema 
of the eyelids and periorbital skin and chronically 
inflamed conjunctiva and cornea; the disease may 
be mild to extremely severe and may consider-
ably impact the vision and life quality (Leonardi 
et al. 2008; Bielory 2010; Guglielmetti et al. 2010). 
Sometimes this disorder is associated with atopic 
dermatitis as a manifestation of an atopic state 
both in humans (Guglielmetti et al. 2010) and dogs 
(Lourenco-Martins et al. 2011). In dogs, the clinical 
features of allergic conjunctivitis encompass bilat-
eral conjunctival hyperaemia (red eye), puffiness 
(chemosis), itch (scraping and patting the eyes) and 
severe discharge; in addition, marginal blepharitis 
and keratitis and secondary (often staphylococcal) 
infections may arise. Chronic patients may develop 
lymphoid hyperplasia, characterised by grossly ob-
servable follicles (follicular conjunctivitis). At the 
cytological exam, the lesion harbours a heterogene-
ous population of T and B cells. Probable diagnosis 
of canine allergic conjunctivitis is made after ruling 
out other potential causes of conjunctivitis and is 
based on anamnesis and on positivity of allergy 
tests (intradermal and serological tests) (Day and 
Crispin 2008; Lourenco-Martins et al. 2011).
Uveitis is another group of syndromes character-
ised by intraocular inflammation, in particular of 
the uvea. Clinically, the iris and ciliary body act to-
gether, while the choroid responds independently. 
Uveitis is generally distinguished into anterior uvei-
tis or iridocyclitis, posterior uveitis or choroiditis 
and panuveitis (inflammation of the whole uveal 
tract) (Townsend 2008; Trbolova 2011). Uveitis 
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occurs when uveal tissue or the vasculature of the 
blood-aqueous barrier or BRB are damaged due to 
a number of causes. Infectious diseases, neopla-
sia and immune-mediated disorders may all cause 
clinical signs of uveitis; therefore, the condition can 
be classified as non-infectious (frequently referred 
as autoimmune) or infectious (Townsend 2008). 
In many cases, uveitis is diagnosed as idiopathic/
immune-mediated (Bergstrom et al. 2017). It is cur-
rently unclear whether the development of uveitis 
reflects a failure of immune privilege. A number 
of observations show the role played by the innate 
immune system in uveitis: for example, the ocular 
tissues (cornea, uvea and retina) synthesise TLRs 
and NOD proteins, and the uveal tract encompasses 
cells crucial for the innate immune response (den-
dritic cells and macrophages); furthermore, the 
innate immune response induces an adaptive au-
toimmune response during non-infectious uveitis 
(Caspi 2010; Willermain et al. 2012). Recently, it 
has been shown that TNF-α concentrations are in-
creased in the aqueous humour of dogs with acute 
anterior uveitis compared to healthy dogs (Durieux 
et al. 2015). In dogs, immune-mediated uveitis gen-
erally develops with acute onset, is characterised by 
severe pain and is associated with blepharospasm, 
lacrimation and photophobia. Visual impairment or 
blindness were reported in some cases. The typical 
ocular features are ciliary injection, corneal oede-
ma, aqueous flare and swollen iris. Uveitis has a 
guarded prognosis (Day and Crispin 2008).
The most common feature of canine uveitis in-
volves local immunopathology. For example, it 
occurs in infectious canine hepatitis induced by 
canine adenovirus type 1; in this case the accumula-
tion of viral immune complexes in the uvea induces 
neutrophil infiltration and secondary corneal en-
dothelial detriment and oedema (so-called “blue 
eye”) (Day and Crispin 2008). A similar condition 
was observed in dogs vaccinated with “old” modi-
fied live canine adenovirus type 1 vaccines; nowa-
days, this problem has been virtually eliminated 
by the use of adenovirus type 2 instead of type 1 
in canine vaccines (Moore 2010; Day et al. 2016).
A peculiar example of non-infectious uveitis is 
the so-called uveodermatological syndrome (also 
known as Vogt-Koyanagi-Harada-like syndrome), 
an autoimmune disorder of dogs in which mel-
anocytes are targeted by the cellular immune re-
sponse (Townsend 2008). Vogt-Koyanagi-Harada 
syndrome is described in human as an uncommon 
multisystemic autoimmune disease that involves 
tissues containing melanin, and affects more fre-
quently dark-skinned people (Mochizuki 2010; 
Greco et al. 2013). In dogs, the skin lesions seem 
to be mediated by T lymphocytes and macrophages 
(TH1 response), whereas the ocular lesions involve 
more likely B cell and macrophage responses (TH2 
response) (Townsend 2008). This disease is fre-
quently reported in the Japanese Akita (genetic 
predisposition), Siberian Husky, Samoyed, Chow 
Chow, Shetland Sheepdog, Golden Retriever, Old 
English Sheepdog, St. Bernard, Irish Setter and 
Australian Setter. Clinical symptoms are depig-
mentation of skin (eyelids, lips, nose, anus, scro-
tum, footpads) with whitening of hair (poliosis) and 
skin (vitiligo) and bilateral ocular lesions (anterior 
uveitis, chorioretinitis, severe retinal detachment 
and optic neuritis) (Day and Crispin 2008).
Finally, neoplasia (primary and secondary) can af-
fect the adnexa, ocular tunics and other structures of 
the eye. Primary ocular neoplasia is more frequent 
than the secondary type. Secondary neoplasia of 
the intraocular components is usually of metastatic 
or multicentric origin (Labelle and Labelle 2013). 
The ocular immune privilege mechanisms may 
favour tumour progression by inhibiting the kill-
ing of malignant cells through direct interference 
with CTL functionality in the eye, or indirectly, by 
abrogation of the effectiveness of CTL-activated 
intratumoural macrophages, which are crucial for 
tumour rejection. Moreover, epigenetic regulation 
of the expression of genes coding for tumour factors 
can enable the generation of CTL-resistant tumour 
variants. Intratumoural macrophages may play a 
crucial role in clearing these variants, since, in 
contrast to CTLs, their killing mechanism is non-
specific. Therefore, the impairment of macrophage 
activity in the eye, aimed at preserving the immune 
privilege by reducing ocular immunopathologies, 
can favour the expansion of tumour escape vari-
ants, and contribute to tumour progression in the 
eye (McKenna and Chen 2010). The impact of 
ocular neoplasms on the structure and function 
of the eye varies according to anatomic location, 
therapeutic options and prognosis; however, in any 
case these growths may have significant impact on 
vision, comfort and longevity. Ocular neoplasia, 
whether primary or metastatic, are relatively rare in 
dogs. The most frequent primary ocular neoplasia 
is the uveal benign melanocytoma (and to a lesser 
extent the uveal malignant melanoma), whereas 
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the most frequent metastatic intraocular tumour 
is lymphosarcoma (Townsend 2008; da Conceicao 
et al. 2010; Labelle and Labelle 2013).
7. With an eye to the future: corneal 
grafting in the dog
In human medicine, an important application of 
ocular immune privilege is corneal transplantation 
(or keratoplasty). Indeed, more than 90% of corne-
al allografts are successful in the absence of tissue 
matching and without systemic immunosuppressive 
therapy (Zhou and Caspi 2010; Taylor 2016). For this 
reason, cornea is the most frequently transplanted 
tissue in the globe, and it is transplanted to treat 
a number of diseases. Penetrating keratoplasty, a 
type of transplantation that involves a full-thickness 
replacement of the cornea, has been the prevalent 
procedure for many decades, and it resolved many 
cases of corneal blindness. Recently a specialist sur-
geon introduced a fundamental change by develop-
ing a new procedure based on transplantation of 
lamellar forms, which selectively replace only the 
impaired layers of the cornea. Deep anterior lamellar 
keratoplasty is replacing penetrating keratoplasty for 
diseases involving the corneal stromal layers, with 
the advantage that there is no risk of rejection (Tan 
et al. 2012), which was primarily due to corneal DCs 
that reach regional lymph nodes and initiate the im-
mune reaction (Knop and Knop 2005b).
Corneal perforation (ulcer) is a common clinical 
sign also in veterinary ophthalmology; in dogs, this 
condition may be caused by infection, inflammation, 
trauma and surgery, and the mainstay of treatment is 
surgery (Lacerda et al. 2017) with the goal of restoring 
structural integrity and preserving maximal corneal 
transparency (Dulaurent et al. 2014). Corneal graft 
surgery has proven effective, but the lack of avail-
able corneal transplants (fresh or frozen) restricts 
the application of this treatment in canine patients 
(Goulle 2012). In veterinary medicine, different sur-
gical biomaterials have been reported to successfully 
resist corneal perforations: among these, the most 
recent ones are grafts of porcine small intestine sub-
mucosa (Goulle 2012), grafts of bovine pericardium 
(Dulaurent et al. 2014) and grafts of porcine urinary 
bladder (Balland et al. 2016). These materials can be 
used for corneal reconstruction, and they represent 
excellent alternatives to conventional conjunctival 
grafts, particularly for veterinary ophthalmologists 
(Balland et al. 2016). If graft rejection occurs, further 
medical or surgical treatment may be required to 
achieve good vision (Lacerda et al. 2017).
8. Concluding remarks and perspectives
Although several studies are under way in dogs 
and other species, the detailed mechanisms under-
lying ocular privilege are not yet completely under-
stood. There is a substantial body of evidence to 
suggest that the cells and molecules of the immune 
system play a crucial role at this immune-privileged 
site. Therefore, the investigation of innate and adap-
tive immune responses in the healthy eye is essential 
for understanding the pathogenesis of ocular in-
flammation and diseases and for selecting the best 
therapeutic approach. The detailed study of ocular 
immunity could indeed suggest novel therapeutic 
strategies for blinding diseases as well as uncover 
more information on acute versus chronic inflam-
mation. Moreover, the canine eye represents a valu-
able model to study human ocular diseases; hence, 
this makes it worthwhile for further investigations.
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